About ARETERNA
About Areterna LLC
Areterna LLC was founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd. to serve customers in the US and Europe.
Synthgene provides materials and services to support mRNA and oligonucleotide manufacturing. Founded in 2018 by a group of passionate nucleic acid chemists, the company’s mission is to debottleneck the raw material supply and develop innovative solutions to support customers in the industry.
The company has a robust quality system and ISO9001 certification to support cGMP manufacturing of mRNA raw materials including NTPs, modified NTPs, and cap analogs. For the GMP raw materials, Drug Master Files have been filed with the FDA.
In addition, Synthgene offers analytical development services and mRNA-related impurity standards and detection kits, LNP screening service, IVT process development, and IVT kits for mRNA research. For solid-phase DNA and RNA synthesis, Synthgene offers high-quality phosphonamidites to support cGMP oligo manufacturing.
With over 200 scientists in R&D and an AI-assisted discovery platform, Synthgene continues to bring new products to the market.
Key Stats
Approved Patents
R&D Scientists
Square Meters of GMP Space
Build the runway for RNA therapeutics to take off
- AI-assisted cap analog discovery platform
- Chemical synthesis – expertise in nucleic acid chemistry and mRNA synthesis
- mRNA sequence design and optimization
- Functional analysis – cell based assays, in-vivo animal studies
- Process development, scale up, and optimization